Search results for "Prolonged release"
showing 4 items of 4 documents
Halloysite nanotubes as a carrier of cornelian cherry (Cornus mas L.) bioactives
2020
Abstract Cornelian cherry fruit extract rich in anthocyanins and iridoids was encapsulated in the halloysite nanotubes in order to obtain a stable nanoscale system for better delivery and prolonged release of bioactive constituents. The cyclic vacuum technique was used for halloysite nanotubes-cornelian cherry composite preparation and the loading of 8.5 wt% was achieved. Pure cornelian cherry extract exhibited antiproliferative effect on HT-29, MCF7, and MRC-5 cells, pristine halloysite nanotubes affected the growth of MCF7 cells, while halloysite nanotubes-cornelian cherry composites demonstrated proliferative activity in all tested cells. The sustained release of anthocyanins was achieve…
Incorporation of dynamic boronate links and Ag nanoparticles into PVA hydrogels for pH-Regulated and prolonged release of methotrexate
2021
Abstract In this study, pH-responsive hydrogels based on PVA-boronate crosslinks were prepared via a simple route and used for controlled and targeted delivery of anticancer drug methotrexate. A double network (DN) hydrogel composed of didiol-boronate/PVA complex as the first network and PVA crystallites generated by a freeze-thaw process as the second one was developed. The swelling of PVA-boronate DN hydrogels demonstrated high sensitivity to multiple stimuli including the pH, temperature, and ionic strength of the media thanks to the dynamic boronate links in the first network. Moreover, unlike previously reported hydrogels based on the boronate linkages, the new DN hydrogels preserved t…
Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Regist…
2019
BACKGROUND: We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. METHODS: Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T.…
Prolonged-release buprenorphine formulations: Perspectives for clinical practice
2020
International audience; Buprenorphine and methadone are the two main opioid agonist treatments approved for opioid use disorder. Buprenorphine is a partial agonist of the mu opioid receptors, which has been merely available through sublingual form until now. In practice, the use of buprenorphine is smoother than that of methadone, and it induces reduced risks of overdose. However, sublingual buprenorphine also exposes to risks (e.g., withdrawal, misuse) and constraints (e.g., daily intake). Three new galenic formulations of prolonged-release buprenorphine (PRB) are being commercialized and should allow some improvements in patients' comfort and safety. This narrative review aims to describe…